Cannabicyclol (CBL) is one of the least known and researched cannabinoids, but is deserving of more research. CBL develops when Cannabichromene (CBC) degrades from overexposure to UV light and oxygen. Therefore, CBL is only available in minute quantities. CBL is considered non-psychoactive, which means that it has therapeutic properties without the intoxicating effect on the body.
Because the research is minimal on Cannabicyclol (CBL), scientists haven’t found much on it. There are assumptions that because it is non-psychoactive, CBL may produce therapeutic effects like other non-psychoactive cannabinoids. The studies that have been conducted on Cannabicyclol (CBL) are more focused on the chemical properties and synthesis, rather than the effect on the human body and endocannabinoid system.
Farmers and harvesters have found that most cannabis strains show a low amount of CBL, making it hard to find in products you see in stores and online. From research, it was found that CBL is harvested over time, it is not a quick process. Most CBL is harvested over years of light exposure to the plant. This process is much like how Cannabinol (CBN) is produced. CBN is produced from the degradation of THC.
It has been said that although there has been minimal research of Cannabicyclol (CBL), it shows true to give off the “entourage effect” like many other cannabinoids. CBL may also have more effects on the human body when mixed with terpenes and other cannabinoids, like CBD, CBN, CBC, and THC.
Formula: C21 H30 O2
IUPAC Name: (1aR- (1a alpha, 3a alpha, 8b alpha, 8c alpha)) - 1a, 2, 3, 3a, 8b, 8c-hexahydro-1,1,3a-trimethyl-6-pentyl-1H- 4-oxabenzo (f) cyclobut (cd) inden-8-ol
Molar mass: 314.469 g/mol